Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity

Bibek Parajuli, Taxiarchis M. Georgiadis, Melissa Fishel, Thomas Hurley

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aldehyde dehydrogenase 3A1 (ALDH3A1) plays an important role in many cellular oxidative processes, including cancer chemoresistance, by metabolizing activated forms of oxazaphosphorine drugs such as cyclophosphamide (CP) and its analogues, such as mafosfamide (MF), ifosfamide (IFM), and 4- hydroperoxycyclophosphamide (4-HPCP). Compounds that can selectively target ALDH3A1 could permit delineation of its roles in these processes and could restore chemosensitivity in cancer cells that express this isoenzyme. Here we report the detailed kinetic and structural characterization of an ALDH3A1-selective inhibitor, CB29, previously identified in a high-throughput screen. Kinetic and crystallographic studies demonstrate that CB29 binds within the aldehyde substrate-binding site of ALDH3A1. Cellular proliferation of ALDH3A1-expressing lung adenocarcinoma (A549) and glioblastoma (SF767) cell lines, as well as ALDH3A1 non-expressing lung fibroblast (CCD-13Lu) cells, is unaffected by treatment with CB29 and its analogues alone. However, sensitivity toward the anti-proliferative effects of mafosfamide is enhanced by treatment with CB29 and its analogue in the tumor cells. In contrast, the sensitivity of CCD-13Lu cells toward mafosfamide was unaffected by the addition of these same compounds. CB29 is chemically distinct from the previously reported small-molecule inhibitors of ALDH isoenzymes and does not inhibit ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2 isoenzymes at concentrations up to 250 μM. Thus, CB29 is a novel small molecule inhibitor of ALDH3A1, which might be useful as a chemical tool to delineate the role of ALDH3A1 in numerous metabolic pathways, including sensitizing ALDH3A1-positive cancer cells to oxazaphosphorines. Enzyme inhibition: Aldophosphamide, an intermediate product of oxazaphosphorine, is metabolized by aldehyde dehydrogenases (ALDH1A1 and ALDH3A1). Selective inhibition of ALDH isoenzymes could reverse this chemoresistant behavior in cancer cells that express ALDH1A1 and ALDH3A1. We report a selective ALDH3A1 inhibitor, its binding mechanism, and its effect on ALDH3A1-positive tumor cells.

Original languageEnglish
Pages (from-to)701-712
Number of pages12
JournalChemBioChem
Volume15
Issue number5
DOIs
StatePublished - Mar 21 2014

Fingerprint

Aldehyde Dehydrogenase
Cytotoxicity
Cyclophosphamide
Cells
Isoenzymes
Neoplasms
perfosfamide
human ALDH3A1 protein
Charge coupled devices
Tumors
Enzyme inhibition
Ifosfamide
Molecules
Kinetics
Fibroblasts
Glioblastoma
Metabolic Networks and Pathways
Aldehydes

Keywords

  • cancer chemoresistance
  • enzyme
  • inhibitors
  • kinetics
  • X-ray crystallography

ASJC Scopus subject areas

  • Biochemistry
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Medicine(all)

Cite this

Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity. / Parajuli, Bibek; Georgiadis, Taxiarchis M.; Fishel, Melissa; Hurley, Thomas.

In: ChemBioChem, Vol. 15, No. 5, 21.03.2014, p. 701-712.

Research output: Contribution to journalArticle

@article{85e28edf51e24a1d8408324da5014586,
title = "Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity",
abstract = "Aldehyde dehydrogenase 3A1 (ALDH3A1) plays an important role in many cellular oxidative processes, including cancer chemoresistance, by metabolizing activated forms of oxazaphosphorine drugs such as cyclophosphamide (CP) and its analogues, such as mafosfamide (MF), ifosfamide (IFM), and 4- hydroperoxycyclophosphamide (4-HPCP). Compounds that can selectively target ALDH3A1 could permit delineation of its roles in these processes and could restore chemosensitivity in cancer cells that express this isoenzyme. Here we report the detailed kinetic and structural characterization of an ALDH3A1-selective inhibitor, CB29, previously identified in a high-throughput screen. Kinetic and crystallographic studies demonstrate that CB29 binds within the aldehyde substrate-binding site of ALDH3A1. Cellular proliferation of ALDH3A1-expressing lung adenocarcinoma (A549) and glioblastoma (SF767) cell lines, as well as ALDH3A1 non-expressing lung fibroblast (CCD-13Lu) cells, is unaffected by treatment with CB29 and its analogues alone. However, sensitivity toward the anti-proliferative effects of mafosfamide is enhanced by treatment with CB29 and its analogue in the tumor cells. In contrast, the sensitivity of CCD-13Lu cells toward mafosfamide was unaffected by the addition of these same compounds. CB29 is chemically distinct from the previously reported small-molecule inhibitors of ALDH isoenzymes and does not inhibit ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2 isoenzymes at concentrations up to 250 μM. Thus, CB29 is a novel small molecule inhibitor of ALDH3A1, which might be useful as a chemical tool to delineate the role of ALDH3A1 in numerous metabolic pathways, including sensitizing ALDH3A1-positive cancer cells to oxazaphosphorines. Enzyme inhibition: Aldophosphamide, an intermediate product of oxazaphosphorine, is metabolized by aldehyde dehydrogenases (ALDH1A1 and ALDH3A1). Selective inhibition of ALDH isoenzymes could reverse this chemoresistant behavior in cancer cells that express ALDH1A1 and ALDH3A1. We report a selective ALDH3A1 inhibitor, its binding mechanism, and its effect on ALDH3A1-positive tumor cells.",
keywords = "cancer chemoresistance, enzyme, inhibitors, kinetics, X-ray crystallography",
author = "Bibek Parajuli and Georgiadis, {Taxiarchis M.} and Melissa Fishel and Thomas Hurley",
year = "2014",
month = "3",
day = "21",
doi = "10.1002/cbic.201300625",
language = "English",
volume = "15",
pages = "701--712",
journal = "ChemBioChem",
issn = "1439-4227",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity

AU - Parajuli, Bibek

AU - Georgiadis, Taxiarchis M.

AU - Fishel, Melissa

AU - Hurley, Thomas

PY - 2014/3/21

Y1 - 2014/3/21

N2 - Aldehyde dehydrogenase 3A1 (ALDH3A1) plays an important role in many cellular oxidative processes, including cancer chemoresistance, by metabolizing activated forms of oxazaphosphorine drugs such as cyclophosphamide (CP) and its analogues, such as mafosfamide (MF), ifosfamide (IFM), and 4- hydroperoxycyclophosphamide (4-HPCP). Compounds that can selectively target ALDH3A1 could permit delineation of its roles in these processes and could restore chemosensitivity in cancer cells that express this isoenzyme. Here we report the detailed kinetic and structural characterization of an ALDH3A1-selective inhibitor, CB29, previously identified in a high-throughput screen. Kinetic and crystallographic studies demonstrate that CB29 binds within the aldehyde substrate-binding site of ALDH3A1. Cellular proliferation of ALDH3A1-expressing lung adenocarcinoma (A549) and glioblastoma (SF767) cell lines, as well as ALDH3A1 non-expressing lung fibroblast (CCD-13Lu) cells, is unaffected by treatment with CB29 and its analogues alone. However, sensitivity toward the anti-proliferative effects of mafosfamide is enhanced by treatment with CB29 and its analogue in the tumor cells. In contrast, the sensitivity of CCD-13Lu cells toward mafosfamide was unaffected by the addition of these same compounds. CB29 is chemically distinct from the previously reported small-molecule inhibitors of ALDH isoenzymes and does not inhibit ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2 isoenzymes at concentrations up to 250 μM. Thus, CB29 is a novel small molecule inhibitor of ALDH3A1, which might be useful as a chemical tool to delineate the role of ALDH3A1 in numerous metabolic pathways, including sensitizing ALDH3A1-positive cancer cells to oxazaphosphorines. Enzyme inhibition: Aldophosphamide, an intermediate product of oxazaphosphorine, is metabolized by aldehyde dehydrogenases (ALDH1A1 and ALDH3A1). Selective inhibition of ALDH isoenzymes could reverse this chemoresistant behavior in cancer cells that express ALDH1A1 and ALDH3A1. We report a selective ALDH3A1 inhibitor, its binding mechanism, and its effect on ALDH3A1-positive tumor cells.

AB - Aldehyde dehydrogenase 3A1 (ALDH3A1) plays an important role in many cellular oxidative processes, including cancer chemoresistance, by metabolizing activated forms of oxazaphosphorine drugs such as cyclophosphamide (CP) and its analogues, such as mafosfamide (MF), ifosfamide (IFM), and 4- hydroperoxycyclophosphamide (4-HPCP). Compounds that can selectively target ALDH3A1 could permit delineation of its roles in these processes and could restore chemosensitivity in cancer cells that express this isoenzyme. Here we report the detailed kinetic and structural characterization of an ALDH3A1-selective inhibitor, CB29, previously identified in a high-throughput screen. Kinetic and crystallographic studies demonstrate that CB29 binds within the aldehyde substrate-binding site of ALDH3A1. Cellular proliferation of ALDH3A1-expressing lung adenocarcinoma (A549) and glioblastoma (SF767) cell lines, as well as ALDH3A1 non-expressing lung fibroblast (CCD-13Lu) cells, is unaffected by treatment with CB29 and its analogues alone. However, sensitivity toward the anti-proliferative effects of mafosfamide is enhanced by treatment with CB29 and its analogue in the tumor cells. In contrast, the sensitivity of CCD-13Lu cells toward mafosfamide was unaffected by the addition of these same compounds. CB29 is chemically distinct from the previously reported small-molecule inhibitors of ALDH isoenzymes and does not inhibit ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, or ALDH2 isoenzymes at concentrations up to 250 μM. Thus, CB29 is a novel small molecule inhibitor of ALDH3A1, which might be useful as a chemical tool to delineate the role of ALDH3A1 in numerous metabolic pathways, including sensitizing ALDH3A1-positive cancer cells to oxazaphosphorines. Enzyme inhibition: Aldophosphamide, an intermediate product of oxazaphosphorine, is metabolized by aldehyde dehydrogenases (ALDH1A1 and ALDH3A1). Selective inhibition of ALDH isoenzymes could reverse this chemoresistant behavior in cancer cells that express ALDH1A1 and ALDH3A1. We report a selective ALDH3A1 inhibitor, its binding mechanism, and its effect on ALDH3A1-positive tumor cells.

KW - cancer chemoresistance

KW - enzyme

KW - inhibitors

KW - kinetics

KW - X-ray crystallography

UR - http://www.scopus.com/inward/record.url?scp=84896397225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896397225&partnerID=8YFLogxK

U2 - 10.1002/cbic.201300625

DO - 10.1002/cbic.201300625

M3 - Article

C2 - 24677340

AN - SCOPUS:84896397225

VL - 15

SP - 701

EP - 712

JO - ChemBioChem

JF - ChemBioChem

SN - 1439-4227

IS - 5

ER -